The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia.
Methods Mol Biol. 2024;2806:31-40. doi: 10.1007/978-1-0716-3858-3_4.
Patient-derived xenograft (PDX) modeling is a valuable tool for the study of leukemia pathogenesis, progression, and therapy response. Engraftment of human leukemia cells occurs following injection into the tail vein (or retro-orbital vein) of preconditioned immunocompromised mice. Injected mice are maintained in a sterile and supportive housing environment until leukemia engraftment is observed, at which time studies such as drug treatments or leukemia sampling can occur. Here, we outline a method for generating PDXs from Acute Myeloid Leukemia (AML) patient samples using tail vein injection; however it can also be readily applied to T- and B- Acute Lymphoblastic Leukemia (ALL) samples.
患者来源异种移植(PDX)模型是研究白血病发病机制、进展和治疗反应的一种有价值的工具。将人白血病细胞注入预先免疫抑制的小鼠尾静脉(或眶后静脉)后,即可发生嵌合。将注射的小鼠置于无菌和支持性的饲养环境中,直到观察到白血病嵌合,此时可以进行药物治疗或白血病样本采集等研究。在这里,我们概述了一种使用尾静脉注射从急性髓系白血病(AML)患者样本中生成 PDX 的方法;然而,它也可以很容易地应用于 T 和 B 急性淋巴细胞白血病(ALL)样本。